Maxitrol

Neomycin sulfate, the active ingredient in Maxitrol, is a combination antibiotic corticosteroid presented as a 3%/0.1%/0.5% ophthalmic suspension for ocular (topical) use. It treats bacterial conjunctivitis, postoperative ocular inflammation and other inflammatory ocular conditions in patients requiring both antimicrobial and anti‑inflammatory therapy.

GNH USA supplies Maxitrol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maxitrol is used to manage bacterial ocular infections and associated inflammation. - Bacterial conjunctivitis: reduces bacterial load and alleviates redness, swelling and discharge. - Post‑operative ocular inflammation: controls inflammation and prevents infection after eye surgery. - Non‑infectious inflammatory ocular conditions: provides anti‑inflammatory relief in conditions such as uveitis or allergic conjunctivitis when bacterial involvement is suspected.

Adverse reactions to Maxitrol may involve the eye or systemic effects, though systemic absorption is minimal.

Common Side Effects: - Burning sensation: transient stinging upon instillation. - Redness: mild conjunctival hyperemia. - Tearing: increased lacrimation. - Foreign body sensation: feeling of grit. - Blurred vision: temporary visual disturbance.

Serious or Rare Side Effects: - Increased intra‑ocular pressure: may lead to glaucoma. - Secondary ocular infection: overgrowth of non‑susceptible organisms. - Corneal ulceration: rare but severe corneal damage. - Allergic reaction: eyelid edema, itching, rash. - Vision loss: rare, requires immediate medical attention.

Before prescribing Maxitrol, clinicians should consider several safety precautions. - Hypersensitivity: avoid use in patients with known allergy to neomycin, polymyxin B, dexamethasone or any component. - Viral infections: do not use in active viral conjunctivitis such as herpes simplex. - Tubercular or fungal eye disease: contraindicated as corticosteroid may worsen. - Contact lens wearers: discontinue lenses before and after instillation to reduce irritation. - Systemic steroid effects: monitor patients at risk for glaucoma or cataract with prolonged use. - Store at room temperature: keep below 25 °C, protect from light and moisture in the original container.

Maxitrol may interact with other ophthalmic or systemic agents.

Major Interactions (Avoid): - Other topical corticosteroids: additive immunosuppression increasing infection risk. - Systemic aminoglycosides: potential additive nephrotoxicity if systemic absorption occurs (rare).

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may reduce anti‑inflammatory effect. - Anticholinergic eye drops: possible increased intra‑ocular pressure. - Live vaccines: systemic corticosteroid effect may diminish vaccine response.